Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Launches ILUMIEN IV Trial To Drive Home Case For OCT

Executive Summary

ILUMIEN IV is the largest-ever prospective randomized trial to compare an intravascular imaging modality, plus angiography, to angiography alone in coronary interventions, according to Abbott. The trial will enroll up to 3,650 patients with high-risk complex disease at 125 centers in North America, Europe and Asia to determine if OCT-guided stenting yields larger vessel diameters and improves clinical outcomes for patients compared to stent procedures guided by standard angiography.

You may also be interested in...



Abbott's Robert Ford: Device Chief Looks Ahead After St. Jude Deal

In an interview with Medtech Insight at this year's JP Morgan Healthcare Conference, the executive VP of medical devices for Abbott Laboratories discussed the firm's recent mega-acquisition of St. Jude Medical, the opportunity in cardiovascular, value-based business models, cybersecurity, and more.

St Jude set to buy LightLab in $90m cash deal

St Jude Medical is to become the first company to offer both optical coherence tomography (OCT) and fractional flow reserve (FFR) technology after agreeing to purchase coronary imaging specialist LightLab Imaging for $90m.

Exec Chat: AngelMed Rolls Out Guardian Cardiac Monitor, Prepares To Go Public

Angel Medical Systems accomplished several major milestones in 2021, including FDA approval of the second-generation version of The Guardian implantable cardiac detection monitor and patient-warning system for acute coronary syndrome events. CEO Brad Snow talked to Medtech Insight about the company's plans to commercialize The Guardian in 2022.

Topics

Related Companies

UsernamePublicRestriction

Register

MT122538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel